Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
FLIPR
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "FLIPR" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier .
3
3 Cited Publications
Target:
Research Areas:
SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd=5.03 nM), exhibits 100-fold selectivity for OX1 over OX2 receptors with IC50 values of 3.76 nM and 531 nM, respectively .
1
1 Cited Publications
Target:
Research Areas:
BAY-390, a chemical probe, is a selective, across species active and brain penetrating TRPA1 inhibitor. BAY-390 inhibits hTRPA1 FLIPR, hTRPA1 Ephys, rTRPA1 FLIPR and rDRG Ephys with IC50s of 16, 82, 63 and 35 nM, respectively. BAY-390 can be used for the research of inflammation .
Target:
Research Areas:
CaV1.3 antagonist-1 is a potent and highly selective CaV1.3 L-type calcium channel (LTCC) antagonist with an IC50 of 1.7 μM. CaV1.3 antagonist-1 inhibits CaV1.3 LTCC >600-fold more potently than CaV1.2 LTCC. CaV1.3 antagonist-1, a cyclopentyl derivative, has the potential for Parkinson's disease research .
Target:
Research Areas:
nAChR agonist 1 is a potent, blood-brain-barrier-permeable, and orally active allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC50 of 0.32 μM in a Ca 2+ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .
Target:
Research Areas:
EP1-antagonist-1 (Compound 27) is an EP1 antagonist with a pKi (FLIPR) of 9.31 and a pIC50 (binding) of 9.88. EP1-antagonist-1 can be used for the study of PGE2-mediated pain .
Cat. No.: HY-14232
CAS No.: 1146395-46-1
Target:
Research Areas:
TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep .
Cat. No.: HY-120636
CAS No.: 1555697-67-0
Target:
Research Areas:
P2Y1 antagonist 1 (compound 10q) is a potent antagonist of P2Y1, with the IC50s of 1.1 nM and 0.24 μM in FLIPR assay and hPA assay, respectively. P2Y1 antagonist 1 plays an important role in antiplatelet research .
Cat. No.: HY-186259
Target:
Research Areas:
TMEM175 agonist 5 (Compound 252) is a TMEM175 agonist with an EC50 of 421 nM in FLIPR cell assays. TMEM175 agonist 5 can be used for the research of neurodegenerative diseases and lysosomal storage disorders .
Cat. No.: HY-186253
CAS No.: 3129653-69-3
Target:
Research Areas:
TMEM175 agonist 1 is a TMEM175 agonist, with a human EC50 of 0.378 μM in FLIPR assays and a human EC50 of 0.886 μM in EP analyses. TMEM175 agonist 1 can be used in the research of Parkinson's disease, dementia with Lewy bodies, rapid eye movement sleep behavior disorder, amyotrophic lateral sclerosis, and lysosomal storage diseases .
Cat. No.: HY-186254
CAS No.: 3129652-92-9
Target:
Research Areas:
TMEM175 agonist 2 is a TMEM175 agonist with an EC50 of 0.0446 μM in human FLIPR assays and an EC50 of 0.0453 μM in human TMEM175 EP assays. TMEM175 agonist 2 can be used in research related to Parkinson's disease, dementia with Lewy bodies, rapid eye movement sleep behavior disorder, amyotrophic lateral sclerosis, and lysosomal storage diseases .
Cat. No.: HY-186257
CAS No.: 3129652-66-7
Target:
Research Areas:
TMEM175 agonist 3 (Compound 123) is a TMEM175 agonist, with an EC50 of 0.044 μM in human TMEM175 FLIPR assays and an EC50 of 0.073 μM in human TMEM175 EP assays. TMEM175 agonist 3 can be used in the research of Parkinson's disease, dementia with Lewy bodies, rapid eye movement sleep behavior disorder, amyotrophic lateral sclerosis, and lysosomal storage diseases .
Cat. No.: HY-10835R
CAS No.: 861238-35-9
Research Areas:
DG-041 (Standard) is the analytical standard of DG-041 (HY-10835). This product is intended for research and analytical applications. DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier .
Cat. No.: HY-186261
Target:
Research Areas:
TMEM175 agonist 7 is a TMEM175 agonist with an EC50 of 543 nM. TMEM175 agonist 7 is applicable to the research of neurodegenerative diseases and lysosomal storage disorders .
Cat. No.: HY-186258
Target:
Research Areas:
TMEM175 agonist 4 (Compound 276) is a TMEM175 agonist. TMEM175 agonist 4 can be used for the research of neurodegenerative diseases and lysosomal storage diseases .
Cat. No.: HY-184490
CAS No.: 3118558-91-8
Target:
Research Areas:
BPR1M492 is a brain-penetrant μ-opioid receptor (MOR) agonist an in vitro EC50 of 0.93 nM in the cAMP inhibition assay and 0.004 nM in the FLIPR Ca 2+ assay without a clear signaling bias between cAMP and β-arrestin-2 pathway. BPR1M492 is a cAMP-biased nociceptin-orphanin FQ opioid peptide agonist. BPR1M492 is a weak cAMP-biased δ/κ-opioid receptor agonist. BPR1M492 demonstrates potent in vivo antinociception and can be used for pain research .
Cat. No.: HY-180584
CAS No.: 1555334-81-0
Target:
Research Areas:
5-HT2A agonist 9 (Compound I-53) is a 5-HT2A agonist with an EC₅₀ of 34 nM. 5-HT2A agonist 9 can be used for the study of mental disorders and central system disorders .
Cat. No.: HY-10898R
CAS No.: 483313-22-0
Research Areas:
SB-674042 (Standard) is the analytical standard of SB-674042 (HY-10898). This product is intended for research and analytical applications. SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd=5.03 nM), exhibits 100-fold selectivity for OX1 over OX2 receptors with IC50 values of 3.76 nM and 531 nM, respectively .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
